Natco Pharma stock gained as much as 32 per cent over the last two days after its marketing partner Mylan received approval from the US Food and Drug Administration (USFDA) for the generic version of Teva’s top-selling multiple sclerosis (MS) drug Copaxone, for both 20 mg/mL and 40 mg/mL formats. The much anticipated approval has improved the investors’ sentiment over the stock as the 40 mg/mL...